Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
30-day single-arm rivaroxaban study in young children with venous thrombosis
NL-OMON41837Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rivaroxaban in Phlebothrombosis and venous thromboembolism (VTE), sponsored by Bayer. Primary endpoint: Incidence of major bleeding and clinically relevant non-major bleeding. Started Feb 2016; status: active, not recruiting.
02
Drugs
rivaroxaban
03
Conditions
Phlebothrombosisvenous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON41837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41837.